CEPI and IVI collaborate on clinical research to expand access to COVID-19 vaccines in Africa

July 20, 2021; Oslo, Norway and Seoul, Republic of Korea: The Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) today announced a new programme of clinical research which aims to expand access to COVID-19 vaccines in…

ACTG announces publication of REPRIEVE sub-study in JAMA Network Open, providing insights into cardiovascular disease risk among people living with HIV

Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced that findings from a sub-study of REPRIEVE (A5332/A5332s, an international clinical trial studying heart disease prevention in people living with HIV) have…

“Smart” segmented ring device delivers medications to stop HIV transmission

Researchers have designed a device that delivers two medications that help stop HIV transmission. Although condom usage is the best strategy for preventing HIV transmission, the researchers are working to design a device that can be used by sex workers…

ACTG announces the addition of two monoclonal antibodies to ACTIV-2 outpatient treatment study for COVID-19

Los Angeles, Calif. – The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the addition of two monoclonal antibodies, BMS-986414 and BMS-986413, to the COVID-19 outpatient treatment study, ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies…

Marking the 40th anniversary of the AIDS epidemic: A paper in the New England Journal of Medicine

June 5, 2021 marks the 40th anniversary of the first report of AIDS cases and the onset of the American AIDS epidemic. In a new, thought-provoking paper in the New England Journal of Medicine , Professor Ronald Bayer and co-author…

Researchers boost potency of an HIV-1 antibody, tracing new pathways for vaccine development

LAWRENCE — Much like coronavirus, circulating HIV-1 viruses mutate into diverse variants that pose challenges for scientists developing vaccines to protect people from HIV/AIDS. “AIDS vaccine development has been a decades-long challenge partly because our immune systems have difficulty recognizing…

One size doesn’t fit all when it comes to products for preventing HIV from anal sex

The initial insights from the study, aptly named DESIRE (Developing and Evaluating Short-acting Innovations for Rectal Use), are being reported on March 6 in a Science Spotlight session at the virtual meeting of the Conference on Retroviruses and Opportunistic Infections…